Menu Search
Equities

OrganiGram Holdings Inc

OGI:TOR

OrganiGram Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)2.51
  • Today's Change-0.07 / -2.71%
  • Shares traded595.98k
  • 1 Year change-9.06%
  • Beta1.0952
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 02-May-24
Select bar for recommendation details.
Recommendations02-May-24
Buy1
Outperform4
Hold2
Underperform0
Sell0

Share price forecast in CAD

The 6 analysts offering 12 month price targets for OrganiGram Holdings Inc have a median target of 4.00, with a high estimate of 5.25 and a low estimate of 2.50. The median estimate represents a 59.36% increase from the last price of 2.51.
High109.2%5.25
Med59.4%4.00
Low-0.4%2.50

Earnings history & estimates in CAD

On Dec 19, 2023, losses of -0.1270 per share. This result exceeded the -0.14 consensus loss of the 3 analysts covering the company
The next earnings announcement is expected on Jul 11, 2024.
Average growth rate-261.98%
OrganiGram Holdings Inc reported annual 2023 losses of -3.61 per share on Dec 19, 2023.
Average growth rate-803.88%
More ▼

Revenue history & estimates in CAD

of 46.04m. This bettered the 39.55m consensus of the 6 analysts covering the company.
Average growth rate+2.47%
OrganiGram Holdings Inc. had revenues for the full year 2023 of 161.64m. This was 10.86% above the prior year's results.
Average growth rate+23.55%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.